ClinicalTrials.gg
CompletedNCT05630001APPULSEUpdated Jan 13, 2026Results posted

Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

A Phase 3 interventional study of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in 8 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Hemoglobinuria, Paroxysmal by Novartis — 5 open to participants now, 7 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Novartis.

Started
2023
the only one that year
Phase 3
5 of 16
1 open now
Registered
8th of 16
by date

Among the 16 studies in Hemoglobinuria, Paroxysmal by Novartis, this one is the only one that started in 2023, is one of 5 in phase 3, and was the 8th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

5 of the 16 studies in Hemoglobinuria, Paroxysmal by Novartis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hemoglobinuria, Paroxysmal by Novartis, or all of them as a file.
02

Study summary

The purpose of the study was to find out if iptacopan is effective and safe in adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switched from their current standard of care treatment (eculizumab or ravulizumab) to study treatment, iptacopan/LNP023.

Read the detailed description

This was a multicenter, single-arm, open label trial, with iptacopan treatment for 24 weeks in adult PNH patients.

This study was comprised of two periods:

  • A Screening period lasting up to 8 weeks.
  • A 24-week open-label, iptacopan Treatment period.

After completion of the treatment period, participants who continued to benefit from the iptacopan treatment based on the study doctor's evaluation were able to join the Roll-over extension study (CLNP023C12001B).

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • Paroxysmal Nocturnal Hemoglobinuria
  • iptacopan
  • single arm open-label
  • Hb≥10 g/dL in response to anti-C5 antibody
  • switch to iptacopan
  • PNH
  • LNP023
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study.
  • Male and female participants ≥ 18 years of age, at the time of ICF signatures and with a diagnosis of PNH confirmed by treating physician.
  • Stable regimen (dose and intervals) of anti-C5 antibody treatment (either eculizumab or ravulizumab) for at least 6 months prior to screening
  • Mean level ≥10 g/dL
  • Vaccination against Neisseria meningitidis and S. pneumoniae infection are required prior to the start of iptacopan treatment.
  • If not received previously, vaccination against Haemophilus influenzae infections is recommended, if available and according to local regulations.
  • Ability to communicate well with the investigator, to understand and comply with the requirements of the study
  • Other protocol -defined inclusion criteria may apply at the end.

Exclusion criteria

Exclusion Criteria:

  • Participation in any other drug trial or use of other investigational drugs at the time of enrollment
  • Patients requiring red blood cell transfusion in the 6 months prior to screening or during screening
  • History of stem cell transplantation or any solid organ transplantation
  • Active systemic bacterial, viral (incl. COVID-19) or fungal infection within 14 days prior to study drug administration
  • Presence of fever ≥ 38.0 °C (100.4 °F) within 7 days prior to study drug administration
  • (HIV) infection (known history of HIV or test positive for HIV antibody at Screening)
  • A history of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus
  • Unstable medical condition including, but not limited to, myocardial ischemia, active gastrointestinal bleeding, coexisting chronic anemia unrelated to PNH, or unstable thrombotic event not amenable to active treatment as judged by the investigator at Screening.
  • History of cancer of any part of the body within the past 5 years,
  • Ongoing drug or alcohol abuse that could interfere with patient's participation in the trial.
  • Any medical condition deemed likely to interfere with the patient's participation in the study
  • Female patients who are pregnant or breastfeeding, or intending to conceive during the course of the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    LNP023 200mg b.i.d.

    Iptacopan (LNP023) at a dose of 200 mg b.i.d. orally

    Drug: Iptacopan

Interventions

  • Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks.

    Also known as: LNP023

06

What researchers measure

Primary outcomes

  1. Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Non-inferiority

    Change in hemoglobin (Hb) levels as mean of visits between Day 126 and Day 168 compared to baseline. Baseline is defined as as the mean of three Hb assessments conducted at the central laboratory: two during screening and the third on Day 1. The estimation of change from baseline in Hb levels was handled by the hypothetical strategy where participants were assumed as if they did not receive RBC transfusions while on treatment (RBC transfusions were expected to be rare). Assuming that participants had stable Hb levels at study entry, the mean change from baseline in Hb level between Day 126 and Day 168 was expected to be unchanged should participants have continued on anti-C5 treatment. Non-inferiority of iptacopan was therefore tested by the null hypothesis (H0) against the alternate hypothesis (H1) comparing the mean change from baseline in Hb level in iptacopan between Day 126 and Day 168 (μ) to -1 g/dL: H0: μ \<= -1, H1: μ \> -1.

    Time frame: Baseline, Day 126 to Day 168

Secondary outcomes

  1. Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Superiority

    Change in hemoglobin (Hb) levels as mean of visits between Day 126 and Day 168 compared to baseline. Baseline is defined as as the mean of three Hb assessments conducted at the central laboratory: two during screening and the third on Day 1.

    Time frame: Baseline, Day 126 to Day 168

  2. Proportion of Hematological Responders to Iptacopan Treatment

    Response defined as Hb ≥12 g/dL assessed between visits Day 126 and Day 168 in the absence of RBC transfusions, on three out of four measurements taken at the visits occurring in last six weeks

    Time frame: Day 126 to Day 168

  3. Proportion of Participants Who Remain Free From Transfusions

    Number of participants with absence of administration of packed RBC transfusions between Day 1 and Day 168

    Time frame: Day 1 to Day 168

  4. Change From Baseline in Absolute Reticulocytes Count (ARC) Levels

    Change from baseline in ARC levels as mean of visits between Day 126 and Day 168

    Time frame: Baseline, Day 126 to Day 168

  5. Percentage Change From Baseline in Lactate Dehydrogenase (LDH) Levels

    Percentage change from baseline in LDH levels as mean of visits between Day 126 and Day 168

    Time frame: Baseline, Day 126 to Day 168

  6. Change From Baseline in Treatment Satisfaction Score Using TSQM-9 Questionnaire

    Difference in scores of the Treatment Satisfaction Questionnaire for Medication(TSQM-9) between baseline and Day 84 and Day 168 assessed after switching from SoC (anti-C5) to iptacopan. TSQM-9 is a patient reported outcomes measure that was designed to assess patients' satisfaction with medication across three domains of effectiveness, convenience and global satisfaction. The TSQM-9 contains 3 questions in each domain. Domain scores range from 0 - 100 with higher scores representing better outcomes for the domain.

    Time frame: Baseline, Day 84 and Day 168

  7. Change From Baseline in Fatigue Score Using FACIT-F Questionnaire

    Change from baseline in patient-reported scores for the functional assessment of chronic illness therapy - Fatigue (FACIT-F) collected at Day 84 and Day 168. The FACIT-F is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best.

    Time frame: Baseline, Day 84 and Day 168

  8. Percentage of Patients Who Had Breakthrough Hemolysis (BTH) Event

    Wilson method is used to calculate the confidence interval for the proportion of patients who had events. The breakthrough is defined clinical if either there is a decrease in hemoglobin levels equal to or more than 2 g/dL (compared to the latest assessment) or if patients present signs or symptoms of gross hemoglobinuria, painful crisis, dysphagia or any other significant clinical PNH-related signs \& symptoms, in presence of laboratory evidence of intravascular hemolysis.

    Time frame: Up to 168 Days

  9. Percentage of Patients Who Had Major Adverse Vascular Events (MAVEs)

    A MAVE is defined as: acute peripheral vascular occlusion, amputation (non-traumatic; nondiabetic), cerebral arterial occlusion/cerebrovascular accident, cerebral venous occlusion, dermal thrombosis, gangrene (non-traumatic; nondiabetic), hepatic/portal vein thrombosis (Budd-Chiari syndrome), mesenteric/visceral arterial thrombosis or infarction, mesenteric/visceral vein thrombosis or infarction, myocardial infarction, pulmonary embolus, renal arterial thrombosis, renal vein thrombosis, thrombophlebitis / deep vein thrombosis, transient ischemic attack, unstable angina or other.

    Time frame: Up to 168 Days

07

Results

Posted Dec 15, 2025

Participant flow

A total of 23 centers; 9 in United States, 4 in Germany, 3 in France, 2 in the United Kingdom, 2 in Italy and one each in Spain, Turkey and Republic of Korea enrolled participants.

Participant flow — Overall Study
MilestoneLNP023 200mg b.i.d.
Started52
Completed51
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryChange in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Non-inferiority

Change in hemoglobin (Hb) levels as mean of visits between Day 126 and Day 168 compared to baseline. Baseline is defined as as the mean of three Hb assessments conducted at the central laboratory: two during screening and the third on Day 1. The estimation of change from baseline in Hb levels was handled by the hypothetical strategy where participants were assumed as if they did not receive RBC transfusions while on treatment (RBC transfusions were expected to be rare). Assuming that participants had stable Hb levels at study entry, the mean change from baseline in Hb level between Day 126 and Day 168 was expected to be unchanged should participants have continued on anti-C5 treatment. Non-inferiority of iptacopan was therefore tested by the null hypothesis (H0) against the alternate hypothesis (H1) comparing the mean change from baseline in Hb level in iptacopan between Day 126 and Day 168 (μ) to -1 g/dL: H0: μ \<= -1, H1: μ \> -1.

Time frame:
Baseline, Day 126 to Day 168
Reported as:
Mean · g/dL
Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Non-inferiority
g/dLLNP023 200mg b.i.d.
Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Non-inferiority2.01 (1.74 to 2.29)
Statistical analysis
  • LNP023 200mg b.i.d. · Mixed Models Analysis · p = <0.0001
SecondaryChange in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Superiority

Change in hemoglobin (Hb) levels as mean of visits between Day 126 and Day 168 compared to baseline. Baseline is defined as as the mean of three Hb assessments conducted at the central laboratory: two during screening and the third on Day 1.

Time frame:
Baseline, Day 126 to Day 168
Reported as:
Mean · g/dL
Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Superiority
g/dLLNP023 200mg b.i.d.
Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Superiority2.01 (1.74 to 2.29)
Statistical analysis
  • LNP023 200mg b.i.d. · Mixed Models Analysis · p = <0.0001
SecondaryProportion of Hematological Responders to Iptacopan Treatment

Response defined as Hb ≥12 g/dL assessed between visits Day 126 and Day 168 in the absence of RBC transfusions, on three out of four measurements taken at the visits occurring in last six weeks

Time frame:
Day 126 to Day 168
Reported as:
Number · Proportion of participants
Proportion of Hematological Responders to Iptacopan Treatment
Proportion of participantsLNP023 200mg b.i.d.
Proportion of Hematological Responders to Iptacopan Treatment92.7 (84.6 to 98.1)
SecondaryProportion of Participants Who Remain Free From Transfusions

Number of participants with absence of administration of packed RBC transfusions between Day 1 and Day 168

Time frame:
Day 1 to Day 168
Reported as:
Number · Proportion of participants
Proportion of Participants Who Remain Free From Transfusions
Proportion of participantsLNP023 200mg b.i.d.
Proportion of Participants Who Remain Free From Transfusions100.0 (93.1 to 100.0)
SecondaryChange From Baseline in Absolute Reticulocytes Count (ARC) Levels

Change from baseline in ARC levels as mean of visits between Day 126 and Day 168

Time frame:
Baseline, Day 126 to Day 168
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Absolute Reticulocytes Count (ARC) Levels
10^9 cells/LLNP023 200mg b.i.d.
Change From Baseline in Absolute Reticulocytes Count (ARC) Levels-89.19 (-95.47 to -82.92)
SecondaryPercentage Change From Baseline in Lactate Dehydrogenase (LDH) Levels

Percentage change from baseline in LDH levels as mean of visits between Day 126 and Day 168

Time frame:
Baseline, Day 126 to Day 168
Reported as:
Mean · Percent change from baseline in LDH
Percentage Change From Baseline in Lactate Dehydrogenase (LDH) Levels
Percent change from baseline in LDHLNP023 200mg b.i.d.
Percentage Change From Baseline in Lactate Dehydrogenase (LDH) Levels-1.30 (-6.56 to 4.26)
SecondaryChange From Baseline in Treatment Satisfaction Score Using TSQM-9 Questionnaire

Difference in scores of the Treatment Satisfaction Questionnaire for Medication(TSQM-9) between baseline and Day 84 and Day 168 assessed after switching from SoC (anti-C5) to iptacopan. TSQM-9 is a patient reported outcomes measure that was designed to assess patients' satisfaction with medication across three domains of effectiveness, convenience and global satisfaction. The TSQM-9 contains 3 questions in each domain. Domain scores range from 0 - 100 with higher scores representing better outcomes for the domain.

Time frame:
Baseline, Day 84 and Day 168
Reported as:
Mean · score on a scale
Change From Baseline in Treatment Satisfaction Score Using TSQM-9 Questionnaire
score on a scaleLNP023 200mg b.i.d.
TSQMS1-Effectiveness Day 8415.08 (9.60 to 20.57)
TSQMS1-Effectiveness Day 16812.54 (5.58 to 19.49)
TSQMS1-Convenience Day 8420.34 (13.68 to 26.99)
TSQMS1-Convenience 16823.86 (17.62 to 30.10)
TSQMS1-Global Satisfaction Day 8414.26 (9.79 to 18.72)
TSQMS1-Global Satisfaction Day 16818.53 (12.87 to 24.19)
SecondaryChange From Baseline in Fatigue Score Using FACIT-F Questionnaire

Change from baseline in patient-reported scores for the functional assessment of chronic illness therapy - Fatigue (FACIT-F) collected at Day 84 and Day 168. The FACIT-F is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best.

Time frame:
Baseline, Day 84 and Day 168
Reported as:
Mean · score on a scale
Change From Baseline in Fatigue Score Using FACIT-F Questionnaire
score on a scaleLNP023 200mg b.i.d.
Day 844.88 (3.23 to 6.53)
Day 1684.29 (1.74 to 6.85)
SecondaryPercentage of Patients Who Had Breakthrough Hemolysis (BTH) Event

Wilson method is used to calculate the confidence interval for the proportion of patients who had events. The breakthrough is defined clinical if either there is a decrease in hemoglobin levels equal to or more than 2 g/dL (compared to the latest assessment) or if patients present signs or symptoms of gross hemoglobinuria, painful crisis, dysphagia or any other significant clinical PNH-related signs \& symptoms, in presence of laboratory evidence of intravascular hemolysis.

Time frame:
Up to 168 Days
Reported as:
Number · Percentage of patients with BTH events
Percentage of Patients Who Had Breakthrough Hemolysis (BTH) Event
Percentage of patients with BTH eventsLNP023 200mg b.i.d.
Percentage of Patients Who Had Breakthrough Hemolysis (BTH) Event0.00 (0.00 to 0.14)
SecondaryPercentage of Patients Who Had Major Adverse Vascular Events (MAVEs)

A MAVE is defined as: acute peripheral vascular occlusion, amputation (non-traumatic; nondiabetic), cerebral arterial occlusion/cerebrovascular accident, cerebral venous occlusion, dermal thrombosis, gangrene (non-traumatic; nondiabetic), hepatic/portal vein thrombosis (Budd-Chiari syndrome), mesenteric/visceral arterial thrombosis or infarction, mesenteric/visceral vein thrombosis or infarction, myocardial infarction, pulmonary embolus, renal arterial thrombosis, renal vein thrombosis, thrombophlebitis / deep vein thrombosis, transient ischemic attack, unstable angina or other.

Time frame:
Up to 168 Days
Reported as:
Number · Percentage of patients with MAVEs
Percentage of Patients Who Had Major Adverse Vascular Events (MAVEs)
Percentage of patients with MAVEsLNP023 200mg b.i.d.
Percentage of Patients Who Had Major Adverse Vascular Events (MAVEs)0.00 (0.00 to 0.14)

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 7 days post treatment for non-serious AEs and 30 days post treatment for serious AEs if patient did not roll over to REP study, up to a maximum duration of 198 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LNP023 200mg b.i.d.0/52 (0%)2/52 (3.8%)25/52 (48.1%)
Most frequent serious events
Most frequent serious events
EventLNP023 200mg b.i.d.
PyrexiaGeneral disorders and administration site conditions1/52
Pneumonia bacterialInfections and infestations1/52
Subdural haematomaInjury, poisoning and procedural complications1/52
Most frequent other events
Most frequent other events
EventLNP023 200mg b.i.d.
HeadacheNervous system disorders9/52
DiarrhoeaGastrointestinal disorders6/52
NauseaGastrointestinal disorders6/52
NasopharyngitisInfections and infestations6/52
FatigueGeneral disorders and administration site conditions4/52
Upper respiratory tract infectionInfections and infestations3/52
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/52

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LNP023 200mg b.i.d.
<=18 years0
Between 18 and 65 years48
>=65 years4
Age, Continuous
Age, Continuous(years)LNP023 200mg b.i.d.
Mean46.0 ± 13.67
Sex: Female, Male
Sex: Female, Male(Participants)LNP023 200mg b.i.d.
Female20
Male32
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LNP023 200mg b.i.d.
White35
Asian4
Not Reported9
Unknown4
08

Study locations

23 sites
  • City Of Hope National Med Center
    Duarte, California 91010, United States
  • USC Norris Cancer Center
    Los Angeles, California 90033, United States
  • Lakes Research
    Miami Lakes, Florida 33014, United States
  • Mass Gen Hosp Cancer Center
    Boston, Massachusetts 02114, United States
  • University Of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Prisma Health Upstate
    Greenville, South Carolina 29615, United States
  • Huntsman Cancer Institute Univ of Utah
    Salt Lake City, Utah 84112 0550, United States
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Nice, 06202, France
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Florence, FI 50134, Italy
  • Novartis Investigative Site
    Bassano del Grappa, VI 36061, Italy
  • Novartis Investigative Site
    Seoul, Seoul 06351, South Korea
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Istanbul, Fatih 34093, Turkey (Türkiye)
  • Novartis Investigative Site
    Leeds, West Yorkshire LS9 7TF, United Kingdom
  • Novartis Investigative Site
    London, SE5 9RS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Oct 2024, 17 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 17 months is below that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2022
First posted
Nov 29, 2022
StartActual
Apr 24, 2023
Primary completionActual
Oct 17, 2024
CompletionActual
Oct 17, 2024
Results first posted
Dec 15, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05630001
Responsible party
Sponsor
First posted
Nov 29, 2022
Start date
Apr 24, 2023
Primary completion
Oct 17, 2024
Completion
Oct 17, 2024
Results posted
Dec 15, 2025
Last update
Jan 13, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iptacopan

Start the discussion